Splash Beverage expands CannEpil license to veterinary applications, targets FDA approval

SPLASH BEVERAGE GROUP, INC.

Expanded exclusive global license for CannEpil to include veterinary therapeutics; royalty 10% of vet net revenue, 15% human.
Initial focus on canine oncology and chronic pain; global veterinary pain market ~$2.6B in 2024, projected $3.8B by 2030.
Company finalizing joint venture with established cannabinoid pharmaceutical firm to lead veterinary development program.
CannEpil is a pharmaceutical-grade CBD/THC oral solution with EU-GMP certification and IND for human program.
Will pursue FDA Center for Veterinary Medicine INAD and Conditional Approval pathways; no assurance of approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.